Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Maintenance Therapy With Histamine Dihydrochloride and Interleukin-2 in Adult Acute Myeloid Leukemia (AML) Patients With Measurable Minimal Residual Disease (MRD)- a Non-interventional Study (NIS)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2013 by University of Ulm.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
Jochen Greiner, University of Ulm
ClinicalTrials.gov Identifier:
NCT01770158
First received: October 9, 2012
Last updated: January 14, 2013
Last verified: January 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: March 2016
  Estimated Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)